This ratio considers the latest price and profits for valuating a stock. Morgan Stanley lifted their price target on Celgene Corp. from $115.00 to $125.00 in a research note on Friday, April 8th.
Advertisement
According to FactSet data, Analysts estimated the EPS for This Quarter.
Several other analysts also recently commented on CELG. The ratio turned negative, as 107 funds sold all Celgene Corporation shares owned while 439 reduced positions. However, Celgene is highly dependent on Revlimid for growth. The firm launched coverage on CELG at Buy. The rating firm gave a Buy rating to this stock in a research note on Jul 15, 2016.Citigroup analysts issued their verdict on Celgene Corporation (NASDAQ:CELG) recently. The research groups have not only released scores but also have updated target price estimates. Valuation Level The valuation of Celgene Corporation is done by analysts by using price-to-earnings ratio. Finally, Leerink Swann reiterated a “market perform” rating and set a $135.00 target price (up previously from $125.00) on shares of Celgene Corp.in a report on Monday. Overweight rating was given by 1 analysts and Underweight rating was given by 0 analysts. They now have a $120.00 price target on the biopharmaceutical company’s stock.
Tenet Healthcare Corp. (NYSE:THC) [Trend Analysis] shows fluctuation in active trade, shares plunged -5.55% to $28.91. The company has a 50-day moving average price of $103.11 and a 200 day moving average price of $103.18. The corporation has a market capitalization of US$90.08 Billion. Celgene Corp. has a one year low of $92.98 and a one year high of $133.59.
Celgene Corporation (NASDAQ:CELG) has been assigned a sentiment score of 0.266. These Analysts measured the Higher, Lower and Mean Estimated EPS for this stock.
The Company has received rating from WSJ analysts. In this report, the EPS is projected at $1.31. During the same quarter in the prior year, the business earned $1.23 earnings per share. Equities analysts expect that Celgene Corp. will post $5.76 earnings per share for the current fiscal year. Moreover, Selkirk Management Llc has 15.53% invested in the company for 248,250 shares. Whittier Trust Co. boosted its position in Celgene Corp.by 0.7% in the second quarter. The stock’s institutional ownership stands at 97.60%. NBT Bank N A NY boosted its position in Celgene Corp.by 0.3% in the fourth quarter. Johnson Financial Group Inc. now owns 9,557 shares of the biopharmaceutical company’s stock valued at $1,145,000 after buying an additional 266 shares in the last quarter. Finally, Meristem LLP boosted its position in Celgene Corp.by 1.7% in the second quarter. Ropes Wealth Advisors LLC boosted its stake in shares of Celgene Corp.by 0.9% in the first quarter. Pitcairn Co. now owns 4,948 shares of the biopharmaceutical company’s stock valued at $488,000 after buying an additional 38 shares during the period.
In other news, insider Robert J. Hugin sold 100,000 shares of the stock in a transaction on Thursday, July 28th. After that the stock’s target price was revised on 07/15/16, approximately two weeks ago. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Hugin Robert J retains 1,032,291 shares in the stock after this transaction. Following the completion of the transaction, the insider is left with a stake of 1,132,291 shares, amounting $131651475. The disclosure for this sale can be found here.
Celgene spokesman Brian Gill stated in an e-mail, “Ms”.
Advertisement
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.
